PT99752A - Processo de preparacao de oligonucleotido modificado marcado de um conjugado e de composicoes farmaceuticas - Google Patents

Processo de preparacao de oligonucleotido modificado marcado de um conjugado e de composicoes farmaceuticas

Info

Publication number
PT99752A
PT99752A PT99752A PT9975291A PT99752A PT 99752 A PT99752 A PT 99752A PT 99752 A PT99752 A PT 99752A PT 9975291 A PT9975291 A PT 9975291A PT 99752 A PT99752 A PT 99752A
Authority
PT
Portugal
Prior art keywords
conjugate
modified oligonucleotide
preparing
pharmaceutical compositions
marking
Prior art date
Application number
PT99752A
Other languages
English (en)
Other versions
PT99752B (pt
Inventor
Constant Adriaan Anton Boeckel
Wilhelmus Henricus Ar Kuijpers
Franciscus Michael Kaspersen
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of PT99752A publication Critical patent/PT99752A/pt
Publication of PT99752B publication Critical patent/PT99752B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pinball Game Machines (AREA)
  • Medicinal Preparation (AREA)
PT99752A 1990-12-10 1991-12-10 Processo de preparacao de oligonucleotido modificado marcado de um conjugado e de composicoes farmaceuticas PT99752B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9002714 1990-12-10

Publications (2)

Publication Number Publication Date
PT99752A true PT99752A (pt) 1992-11-30
PT99752B PT99752B (pt) 1999-05-31

Family

ID=19858122

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99752A PT99752B (pt) 1990-12-10 1991-12-10 Processo de preparacao de oligonucleotido modificado marcado de um conjugado e de composicoes farmaceuticas

Country Status (15)

Country Link
EP (1) EP0490434B1 (pt)
JP (1) JP3143506B2 (pt)
KR (1) KR920012106A (pt)
AT (1) ATE190621T1 (pt)
AU (1) AU646118B2 (pt)
CA (1) CA2057292A1 (pt)
DE (1) DE69132044T2 (pt)
ES (1) ES2144992T3 (pt)
FI (1) FI915780L (pt)
HU (1) HUT63191A (pt)
IE (1) IE914220A1 (pt)
NO (1) NO914839L (pt)
NZ (1) NZ240926A (pt)
PT (1) PT99752B (pt)
ZA (1) ZA919694B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
AU5733994A (en) * 1992-11-30 1994-06-22 Wellcome Foundation Limited, The Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide
US5571680A (en) * 1994-01-21 1996-11-05 Beckman Instruments, Inc. Homogeneous immunoassays and enzyme based assays of analytes using capillary electrophoresis
IL114237A (en) * 1994-07-14 2000-08-31 Schering Ag Oligonucleotide conjugates and diagnostic processes utilizing the same
GB2291877B (en) * 1994-08-01 1998-09-23 Tom Robin Caine Boyde Interlinking at least two protein molecules via nucleic acid chains
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
US20010051348A1 (en) 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
WO2001054731A2 (en) * 2000-01-28 2001-08-02 National University Of Singapore Ligand conjugates and methods for preparing same
EP1283674A4 (en) * 2000-03-24 2005-04-27 Univ Temple TREATMENT OF PROLIFERATIVE DISORDERS BY EXPOSURE TO DIRECT RADIATION OF CELL CORES CONTAINING NUCLEAR TARIFFS
DE10361502A1 (de) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Kosmetische oder pharmazeutische Zubereitungen enthaltend Superstruktur-bildende Nukleinsäure-Sequenzen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) * 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
WO1989005853A1 (en) * 1987-12-15 1989-06-29 Synthetic Genetics Nucleic acid chelate conjugate as therapeutic and diagnostic agents
EP0353290A4 (en) * 1988-01-21 1990-09-05 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5109124A (en) * 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
DK0462145T3 (da) * 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
CA2049361A1 (en) * 1989-04-18 1990-10-19 Jack S. Cohen Oligodeoxynucleotides with 5'-linked chemical groups, method of product thereof and use thereof

Also Published As

Publication number Publication date
KR920012106A (ko) 1992-07-25
NZ240926A (en) 1993-11-25
FI915780A7 (fi) 1992-06-11
ES2144992T3 (es) 2000-07-01
JPH04290897A (ja) 1992-10-15
NO914839L (no) 1992-06-11
EP0490434B1 (en) 2000-03-15
FI915780A0 (fi) 1991-12-09
EP0490434A1 (en) 1992-06-17
AU646118B2 (en) 1994-02-10
ATE190621T1 (de) 2000-04-15
CA2057292A1 (en) 1992-06-11
HU913867D0 (en) 1992-02-28
PT99752B (pt) 1999-05-31
FI915780L (fi) 1992-06-11
HUT63191A (en) 1993-07-28
JP3143506B2 (ja) 2001-03-07
ZA919694B (en) 1992-10-28
NO914839D0 (no) 1991-12-09
DE69132044D1 (de) 2000-04-20
AU8896091A (en) 1992-06-11
DE69132044T2 (de) 2000-09-28
IE914220A1 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
PT983087E (pt) Composicao de vacina multivalente com veiculo misto
HUT62010A (en) Process for producing oligonucleotide analogs comprising terminal 3 - 3, or 5 - 5- intermolecular bonds
IS4408A (is) Telomerasi úr spendýrum
ATE144523T1 (de) Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen
FR2680507B1 (fr) Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IT1262896B (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
PT99954A (pt) Processo de preparacao de moleculas de ligacao labeis aos acidos e de composicoes farmaceuticas
DE69519521D1 (de) Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
ATE190621T1 (de) Markierte, modifizierte oligonokleotiden
PT98375A (pt) Processo de preparacao de compostos de piperidina e de composicoes farmaceuticas
BR9811855A (pt) Processo para preparação de ácido l-ascórbico
NO995858L (no) Ny klasse kationiske nukleinsyre-overføringsmidler
IL110968A0 (en) Nucleosides, nucleotides and oligonucleotides comprising tris-4,4',4"-tert-butylphenylmethyl, as protected group and their preparation
NZ510116A (en) Tricyclic delta-3-piperidines as pharmaceuticals
FR2704547B1 (fr) Nouveaux composés pyrrolopyraziniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
BG101163A (bg) 8-флуоро-антрациклини, процеси за тяхното получаване и фармацевтични състави съдържащи ги
BR9914775A (pt) Processo quìmico para preparação deintermediários
BR0000184A (pt) Processo para a preparação de compostos heterocìclicos
IL95166A0 (en) Renin-inhibiting amino oligohydroxy derivatives
BR9811875A (pt) Composição e processo de tratamento de câncer com ácido tânico e complexos de tanino
AU682278B2 (en) Oligomer carrier molecules in which marker groups and haptens are selectively incorporated

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920707

FG3A Patent granted, date of granting

Effective date: 19990222

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20000831